We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The House of Representatives Friday approved the 21st Century Cures Act by a vote of 344 to 77, moving focus to the Senate where efforts have begun to develop comparable legislation. Read More
Manufacturers may obtain marketing authorization based on less-than-comprehensive applications if they supplement their filings with clinical data. Read More
The FDA handed Gilead Sciences an eight-observation Form 483 for an array of production issues, including poor manufacturing instructions and processing procedures. Read More
Excipient makers preparing for the new GMP standard NSF/IPEC/ANSI 363 should be aware they are expected to police themselves to determine if they are meeting manufacturing requirements for their products. Read More
Increasing data is driving collaboration among drugmakers, insurers, health systems and technology firms to deliver cost-effective and improved treatments to patients, a just-released PwC report concludes. Read More
The FDA’s Oncologic Drugs Advisory Committee largely appeared to agree that Eli Lilly’s lung cancer drug necitumumab offers some late-stage lung cancer patients increased survival time, despite an increased risk of adverse events, but didn’t vote on whether to recommend the product for approval. Read More
A Delaware state judge dismissed with prejudice a decade-old lawsuit filed by six New York Teamsters organizations against AstraZeneca alleging consumer fraud over marketing of the heartburn drug Nexium, saying the purchasers had no evidence they’d been harmed. Read More
Teva said Wednesday that it has launched a generic version of Janssen Pharmaceutical’s migraine drug Axert in the U.S., following receipt of FDA approval. Read More